AbbVie
ABBV
3,380 hedge funds and large institutions have $228B invested in AbbVie in 2024 Q1 according to their latest regulatory filings, with 221 funds opening new positions, 1,333 increasing their positions, 1,491 reducing their positions, and 115 closing their positions.
92% more first-time investments, than exits
New positions opened: 221 | Existing positions closed: 115
29% more call options, than puts
Call options by funds: $3.29B | Put options by funds: $2.55B
15% more capital invested
Capital invested by funds: $198B → $228B (+$30.3B)
11% more funds holding in top 10
Funds holding in top 10: 202 → 224 (+22)
2% more funds holding
Funds holding: 3,322 → 3,380 (+58)
1.24% less ownership
Funds ownership: 72.3% → 71.06% (-1.2%)
11% less repeat investments, than reductions
Existing positions increased: 1,333 | Existing positions reduced: 1,491
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.72B |
| 2 |
Franklin Resources
San Mateo,
California
|
+$616M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$538M |
| 4 |
Capital International Investors
Los Angeles,
California
|
+$536M |
| 5 |
DZ Bank
Frankfurt Am Main,
Germany
|
+$397M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$5.68B |
| 2 |
Pacer Advisors
Malvern,
Pennsylvania
|
-$423M |
| 3 |
Bank of New York Mellon
New York
|
-$391M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$315M |
| 5 |
Charles Schwab
San Francisco,
California
|
-$299M |
ABBV Hedge Fund Activity: Q1 2024 in Review
3,380 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q1 2024, worth a combined $228B — up 15% from $198B a quarter earlier.
Buyers outnumbered sellers: 221 funds opened new ABBV positions and 115 closed out — a net gain of 106 holders — while 1,333 added to existing stakes and 1,491 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.72B. The largest seller was Morgan Stanley, cutting an estimated $5.68B.
- 3,380 institutional investors held AbbVie (ABBV) as of Q1 2024, up from 3,322 in Q4 2023.
- Funds reported $228B of AbbVie stock for Q1 2024, up 15% quarter-over-quarter.
- 221 funds opened new AbbVie positions in Q1 2024 and 115 closed out, a net change of +106 holders.
- The largest AbbVie buyer in Q1 2024 was Vanguard Group, an estimated $1.72B added.
- The largest AbbVie seller in Q1 2024 was Morgan Stanley, an estimated $5.68B sold.
Based on aggregated 13F filings for Q1 2024.